Overcoming the Solvent Front: How Jideytro Validates Nuvalent's Precision Oncology Playbook
Dr. Dereck Mush, MD, MBA
SimBioSys
Precision oncology software for breast cancer recurrence prognosis and MRI visualization.
What they do
SimBioSys develops TumorSight Risk, cleared under FDA K260023 on September 25, 2026, for recurrence-risk estimates in a specified breast cancer population. TumorSight Viz is a separate MRI visualization product. The clearance does not establish diagnosis, treatment benefit or reduced re-excision rates.
The record
- Vertical
- Oncology
- Sub-segment
- Precision oncology
- Product type
- Software as a medical device
- Stage
- Headquarters
- Not disclosed
- Region
- North America
- Founded
- Not disclosed
- Total funding
- Undisclosed
Also in Oncology
Related on The Signal
Dr. Dereck Mush, MD, MBA
Breaking the PMA Bottleneck: How FDA's Class II Reclassification Accelerates Precision Oncology
Dr. Dereck Mush, MD, MBA
Liquid biopsy monitoring is turning precision oncology into a continuous process, not a one time test
Dr. Dereck Mush, MD, MBA
Beyond PD-L1: How the I3LUNG Consortium Validated Multimodal AI in 2,365 Advanced Lung Cancer Patients
Dr. Dereck Mush, MD, MBA